ArticleJournal of nanobiotechnology2026
The antifibrotic effects of a click chemistry-based albumin nanocomplex in an idiopathic pulmonary fibrosis model.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by excessive extracellular matrix (ECM) accumulation and irreversible alveolar damage. Although currently available antifibrotic drugs can slow disease progression, their clinical utility is limited by systemic side effects and a lack of organ and cell specificity. Apigenin has been shown to exhibit antifibrotic properties by modulating reactive oxygen species (ROS) and inhibiting of the transforming growth factor-beta (TGF-β) signaling pathway. However, its poor solubility and bioavailability restrict its therapeutic application. To address these limitations, we developed an albumin-dibenzycyclooctyne-glucose/apigenin (AD-Glc/Api) nanocomplex designed for targeted delivery to fibrotic lung tissue.
resultIn this nanocomplex, albumin enhances the pharmacokinetic properties, while glucose modification enhances cellular uptake in vitro. In an IPF mouse model, positron emission tomography (PET) imaging demonstrated pulmonary-associated signals of [
conclusionsAD-Glc/Api is an effective antifibrotic nanotherapeutic, with efficacy driven by improved systemic circulation and enhanced cellular uptake. This theranostic platform represents a promising strategy for improving the diagnosis and treatment of IPF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.